Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions

Pharmacological Research

Volumn 60, Issue 1, 2009, Pages 24-32

  Balakumar, Pitchai ^a   Arora, Mandeep Kumar ^a   Ganti, Subrahmanya S ^a   Reddy, Jayarami ^a   Singh, Manjeet ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Diabetes; Diabetic nephropathy; Pharmacological interventions; Target sites

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; ENALAPRIL; EPLERENONE; FAD 286; FOSINOPRIL; IMIDAPRIL; IRBESARTAN; ISRADIPINE; LACIDIPINE; LISINOPRIL; LOSARTAN; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; OLMESARTAN; PAICALCITOL; PERINDOPRIL; RAMIPRIL; RUBOXISTAURIN; SPIRONOLACTONE; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VITAMIN D DERIVATIVE;

ALBUMINURIA; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GLOMERULOSCLEROSIS; HUMAN; HYPERGLYCEMIA; KIDNEY FUNCTION; MICROALBUMINURIA; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ALDOSTERONE ANTAGONISTS; ANIMALS; CALCIUM CHANNEL BLOCKERS; DIABETIC NEPHROPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PROTEIN KINASE C; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 67349117682     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.02.002     Document Type: Review

References (135)

1. Fowler M.J. Microvascular and macrovascular complications of diabetes. Clin Diab 26 (2008) 77-82
2. Schrijvers B.F., Vriese A.S.D., and Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endo Rev 25 (2004) 971-1010
3. Kanwar Y.S., Wada J., Sun L., Xie P., Wallner E.I., Chen S., et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 233 (2008) 4-11
4. Balakumar P., Chakkarwar V.A., Krishan P., and Singh M. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?. Biomed Pharmacother (2008) 10.1016/j.biopha.2008.08.008
5. Balakumar P., Chakkarwar V.A., Kumar V., Jain A., Reddy J., and Singh M. Experimental models for nephropathy. J Renin Angiotensin Aldosterone Syst 9 (2008) 189-195
6. Huang Y.H., Wang H.T., Zhu Q.Z., Zhang H., Shen W., and Wang Y. Combination therapy with losartan and fosinopril for early diabetic nephropathy. Di Yi Jun Yi Da Xue Xue Bao 23 (2004) 963-965
7. Balakumar P., Chakkarwar V.A., and Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem 320 (2009) 149-162
8. Anderson S., Jung F.F., and Inglefinger J.R. Renin-angiotensin system in diabetic rats: functional, immunohistochemical, and molecular biologic correlations. Am J Physiol 265 (1993) F477-F486
9. Singh R., Singh A.K., Alavi N., and Leehey D.J. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 14 (2002) 873-880
10. Kagami S., Border W.A., Miller D.E., and Noble N.A. Angiotensin II stimulated extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular cells. J Clin Invest 93 (1994) 2431-2437
11. Kagami S., Kuhara T., Okada K., Kuroda Y., Border W.A., and Noble N.A. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 51 (1997) 664-671
12. Wilson H.M., Haites N.E., and Booth N.A. Effect of angiotensin II on plasminogen activator inhibitor-1 production by cultured human mesangial cells. Nephron 77 (1997) 197-204
13. Singh R., Alavi N., Singh A.K., and Leehey D.J. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48 (1999) 2066-2073
14. Giacchetti G., Sechi L.A., Rilli S., and Carey R.M. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metabol 16 (2005) 120-126
15. Ortega M.R., Ruperez M., Esteban V., Vita J.R., Lopez E.S., Carvajal G., et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21 (2006) 16-20
16. Gojo A., Utsunomiya K., Taniguchia K., Yokotaa T., Ishizawaa S., Kanazawaa Y., et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 568 (2007) 242-247
17. Ha H., and Kim K.H. Amelioration of diabetic microalbuminuria and lipid peroxidation by captopril. Yonsei Med J 33 (1992) 217-223
18. Rodby R.A., and Lewis E.J. ACE Inhibition in diabetic patients: economic implications. Pharmacoeconomics 10 (1996) 315-320
19. Yousef W.M., Morsey M.D., Waheed M.M.A., Ghanayeem N.M., and Omar A.H. Effect of some calcium channel blockers in experimentally induced diabetic nephropathy in rats. Iranian J Pharmacol Ther 3 (2004) 45-56
20. Amann B., Tinzmann R., and Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26 (2003) 2421-2425
21. Katayamaa S., Kikkawab R., Isogaic S., Sasakia N., Matsuurad N., Tajimae N., et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract 55 (2002) 113-121
22. Gerstein H.C. Diabetes and the HOPE study: implications for macrovascular and microvascular disease. Int J Clin Pract Suppl 117 (2001) 8-12
23. McLennan S.V., Kelly D.J., Cox A.J., Cao Z., Lyons J.G., Yue D.K., et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 45 (2002) 268-275
24. Lin H., Huang S., Mi X., and Sha Z. Effects of cilazapril on the expression of vascular endothelial growth factor and intercellular adhesion molecule-1 in diabetic rat glomeruli. Sichuan Da Xue Xue Bao Yi Xue Ban 34 (2003) 694-697
25. Yongman L.V., Junwu D., Xiaochun N., and Xiaocheng L. Renoprotective effect of benazepril on diabetic nephropathy mediated by P42/44MAPK. J Huazhong Uni Sci Technol 25 (2005) 32-35
26. Eijkelkamp W.B.A., Zhang Z., Remuzzi G., Parving H.H., Cooper M.E., Keane W.F., et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial. J Am Soc Nephrol 18 (2007) 1540-1546
27. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 345 (2001) 851-860
28. Hunsicker L.G. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. J Manag Care Pharm 10 (2004) S12-S17
29. Pugsley M.K. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc West Pharmacol Soc 48 (2005) 35-38
30. Bakris G.L., Weir M.R., Dequattro V., and Mcmahon F.G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54 (1994) 1283-1289
31. Song J.H., Cha S.H., Lee H.J., Lee S.W., Park G.H., Lee S.W., et al. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Nephrol Dial Transplant 21 (2005) 683-689
32. Zhang Z., Zhang Y., Ning G., Deb D.K., Kong J., and Li Y.C. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 105 (2008) 15896-15901
33. Cha D.R., Kang Y.S., Han S.Y., Jee Y.H., Han K.H., Kim H.K., et al. Role of aldosterone in diabetic nephropathy. Nephrol Carlton 10 (2005) S37-S39
34. Sirgay H.M., and Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol 93 (2008) 817-824
35. Remmuzzi G., Cattaneo D., and Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 19 (2008) 1459-1462
36. Han S.Y., Kim C.H., Kim H.S., Jee Y.H., Song H.K., Lee M.H., et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17 (2006) 1362-1372
37. Takebayashi K., Matsumoto S., Aso Y., and Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metabol 91 (2006) 2214-2217
38. Kang Y.S., Ko G.J., Lee M.H., Song H.K., Han S.Y., Han K.H., et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 24 (2009) 73-84
39. Nielsen B., Gronback H., Osterby R., and Olyvbjerg A. Effect of nitrendipine and nisoldipine on renal structure and function in long-term experimental diabetes in rats. Am J Kidney Dis 36 (2000) 368-377
40. Lapchynska I.I., Zhurylo TIe, Seliuk M.M., and Hromova A.I. Therapeutic efficacy of lacidipine in patients with chronic glomerulonephritis and diabetic nephropathy. Lik Sprava 2 (2002) 116-120
41. Baba T., Tomiyama T., Murabayashi S., and Takebe K. Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin-dependent) diabetic patients with and without nephropathy. Eur J Clin Pharmacol 38 (1990) 425-429
42. Sabuncu T., Vural H., Dalmaz M., Nazligur Y., Kocyigit A., Erel O., et al. Metabolic effects of isradipine in normotensive NIDDM patients with microalbuminuria. Tr J Med Sci 28 (1998) 631-636
43. Kopf D., Schmitz H., Beyer J., Frank M., Bockisch A., and Lehnert H. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy. Diabetes Nutr Metab 14 (2001) 245-252
44. Kornatowska K.K.D., Szram S., Kornatowski T., Szadurski L.S., Dziora J.K., and Bartosz G. The effect of verapamil on the antioxidant defence system in diabetic kidney. Clin Chim Acta 332 (2002) 105-112
45. Guorong M., Allen T.J., Cooper M.E., and Cao Z. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. Kidney Int 66 (2004) 1090-1098
46. Muragundla A., and Kanwaljit C. Diltiazem attenuates oxidative stress in diabetic rats. Renal Failure 27 (2005) 335-344
47. Salako B.L., Finomo F.O., Kadiri S., Arije A., and Olatosin A.O. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type II diabetic nephropathy. Afr J Med Med Sci 31 (2002) 53-57
48. Baba S. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 54 (2003) 191-201
49. Toto R.D., Tian M., Fakouhi K., Champion A., and Bacher P. Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. J Clin Hypertens (Greenwich) 10 (2008) 761-769
50. Border W.A., and Noble N.A. Evidence that TGF-β should be a therapeutic target in diabetic nephropathy. Kidney Int 54 (1998) 1390-1391
51. Hoffman B.B., Sharma K., and Ziyadeh F.N. Potential role of TGF-β in diabetic nephropathy. Mineral Electro Metab 24 (1998) 190-196
52. Goldfarb S., and Ziyadeh F.N. TGF-β: a crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc 112 (2001) 27-33
53. Ziyadeh F.N. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 15 (2004) S55-S57
54. Jeong H.S., Park K.K., Kim S.P., Choi I.J., Lee I.K., and Kim H.C. Effect of antisense TGF-β1 oligodeoxynucleotides in streptozotocin-induced diabetic rat kidney. J Kor Med Sci 19 (2004) 374-383
55. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42 (1993) 450-456
56. Park I.S., Kiyomoto H., Abboud S.L., and Abboud H.E. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 46 (1997) 473-480
57. Hong S.W., Isono M., Chen S., Cruz M.C., Han D.C., and Ziyadeh F.N. Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor and activation of the smad signaling pathway in the db/db mouse. Am J Pathol 158 (2001) 1653-1663
58. Inoki K., Haneda M., Ishida T., Mori H., Maeda S., Koya D., et al. Role of mitogen-activated protein kinases as downstream effectors of transforming growth factor-β in mesangial cells. Kidney Int 58 (2000) S76-80
59. Haneda M., Hoya D., Isono M., and Kikkawa R. Overview of glucose signalling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 14 (2003) 1374-1382
60. Connolly S.B., sadlier D., Kieran N.E., doran P., and Brady H.R. Transcriptome profiling and the pathogenesis of diabetic complications. J Am Soc Nephrol 14 (2003) S279-S283
61. Hill C., Flyvbjerg A., Rasch R., Bak M., and Logan A. Transforming growth factor-β antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 170 (2001) 647-651
62. Benigni A., Zojaa C., Campanaa M., Cornaa D., Sangallia F., Rottolia D., et al. Beneficial effect of TGF-β antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol 104 (2006) e158-e168
63. Mizuno S., and Nakamura T. Suppressions of chronic glomerular injuries and TGF-β1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Renal Physiol 286 (2004) F134-F143
64. Russo L.M., Re E.D., Brown D., and Lin H.Y. Evidence for a role of transforming growth factor (TGF)-β1 in the induction of postglomerular albuminuria in diabetic nephropathy. Amelioration by soluble (TGF)-β1 type II receptor. Diabetes 56 (2007) 380-388
65. Bohlender J.M., Franke S., Stein G., and Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 289 (2005) F645-F659
66. Wautier J.L., and Guillausseau P.J. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27 (2001) 535-542
67. Forbes J.M., Cooper M.E., Oldfield M.D., and Thomas M.C. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 14 (2003) S254-S258
68. Wendt T., Tanji N., Guo J., Hudson B.I., Bierhaus A., Ramasamy R., et al. Glucose, glycation, and rage: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14 (2003) 1383-1395
69. Yang C.W., Vlassarat H., Peten E.P., He C.J., Striker G.E., and Striker L.J. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91 (1994) 9436-9440
70. Kim Y. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-β. J Lab Clin Med 138 (2003) 59-68
71. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., and Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280 (2001) E685-E694
72. Tsuchida K., Makita Z., Yamagishi S., Atsumi T., Miyoshi H., Obara S., et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42 (1999) 579-588
73. Forbes J.M., Soulis T., Thallas V., Panagiotopoulos S., Long D.M., Vasan S., et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44 (2001) 108-114
74. Bonke V.T., Lindschau C., Rizkalla B., Bach L.A., Boner G., Meier M., et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C dependent pathway. Diabetes 53 (2004) 2921-2930
75. Twigg S.M., Cao Z., Mclennan S.V., Burns W.C., Brammar G., Forbes J.M., et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143 (2002) 4907-4915
76. Izuhara Y., Nangaku M., Takizawa S., Takahashi S., Shao J., Oishi H., et al. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 23 (2008) 497-509
77. Figarola J., Loera S., Weng Y., Shanmugam N., Natarajan R., and Rahbar S. LR-90 prevents dyslipidaemia and diabetic nephropathy in the zucker diabetic fatty rat. Diabetologia 51 (2008) 882-891
78. Davis B.J., Forbes J.M., Thomas M.C., Jerums G., Burns W.C., Kawachi H., et al. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 47 (2004) 89-97
79. Craven P.A., and DeRubertis F.R. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats possible mediation by glucose. J Clin Invest 83 (1989) 1667-1675
80. Koya D., Jirousek M.R., Lin Y.W., Ishii H., Kuboki K., and King G.L. Characterization of protein kinase c β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100 (1997) 115-126
81. Hoshi S., Nomoto K., Kuromitsu J., Tomari S., and Nagata M. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun 290 (2002) 177-184
82. Lee E.Y., Chung C.H., Kim J.H., Joung H.J., and Hong S.Y. Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes. Nephrol Dial Transplant 21 (2006) 1496-1503
83. Kikkawa R., Koya D., and Haneda M. Progression of diabetic nephropathy. Am J Kidney Dis 41 (2003) S19-21
84. Tuttle K.R., and Anderson P.W. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 42 (2003) 456-465
85. Kelly D.J., Chanty A., Gow R.M., Zhang Y., and Gilbert R.E. Protein kinase-cβ inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 16 (2005) 1654-1660
86. Kelly D.J., Buck D., Cox A.J., Zhang Y., and Gilbert R.E. Effects on protein kinase C-β inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am J Physiol Renal Physiol 293 (2007) F565-F574
87. Deinum J., Tarnow L., Gool J.M.V., Bruin R.A.D., Derkx F.H.M., Schalekamp M.A.D.H., et al. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrol Dial Transplant 14 (1999) 1904-1911
88. Huang Y., Noble N.A., ZhangJ, Xu C., and Border W.A. Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 72 (2007) 45-52
89. Kelly D.J., Zhang Y., Moe G., Naik G., and Gilbert R.E. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50 (2007) 2398-2404
90. Schernthaner G. Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy. Nat Clin Pract Nephrol 4 (2008) 656-657
91. Ingelfinger J.R. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med 358 (2008) 2503-2505
92. Peng F., Wu D., Gao B., Ingram A.J., Zhang B., Chorneyko K., et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 57 (2008) 1683-1692
93. Yuichi K., Muneharu Y., Toshihiko I., Taketoshi K., Keishi H., Naomi H., et al. A rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 192 (2007) 595-603
94. Soma J., Sugawara T., Huang Y.D., Nakajima J., and Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 92 (2002) 693-698
95. Mifsud S., Kelly D.J., Qi W., Zhang Y., Pollock C.A., Wilkinson-Berka J.L., et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 95 (2003) 83-91
96. Akahori H., Ota T., Torita M., Ando H., Kaneko S., and Takamura T. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. J Pharmacol Exp Therap 314 (2005) 514-521
97. Soma J., Sato K., Saito H., and Tsuchiya Y. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 21 (2006) 2795-2799
98. Tokuyama H., Kelly D.J., Cox A., Zhang Y., Thai K., Nikolic-Paterson D.J., et al. Tranilast ameliorates experimental mesangial proliferative glomerulonephritis. Nephron Exp Nephrol 109 (2008) e1-e7
99. Sugaru E., Nakagawa T., Kishino M.O., Nagamine J., Tokunaga T., Kitoh M., et al. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am J Physiol Renal Physiol 290 (2006) F813-F820
100. Bonke V.T., Sci B.A., Thorpe S.R., Coughlan M.T., Fukami K., Yap F.Y.T., et al. Inhibition of NADPH oxidase prevents AGE mediated damage in diabetic nephropathy through a protein kinase C-α dependent pathway. Diabetes 57 (2008) 460-469
101. Nam S.M., Lee M.Y., Koh J.H., Park J.H., Shin J.Y., Shin Y.G., et al. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property. Diabetes Res Clin Pract 83 (2008) 176-182
102. Szabo C., Biser A., Benko R., Bottinger E., and Susztak K. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic leprdb/db mice. Diabetes 55 (2006) 3004-3012
103. Minchenko A.G., Stevens M.J., White L., Abatan O.I., Komjati K., Pacher P., et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 17 (2003) 1514-1516
104. Sasser J.M., Sullivan J.C., Hobbs J.L., Yamamoto T., Pollock D.M., Carmines P.K., et al. Endothelin a receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18 (2007) 143-154
105. Xu M., Dai D.Z., and Dai Y. Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU 0213 in rats. Am J Nephrol 29 (2009) 252-256
106. Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E, et al. for the SPP301 (Avosentan) endothelin antagonist evaluation in diabetic nephropathy study investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; doi:10.1681/ASN.2008050482.
107. Drel V.R., Pacher P., Stevens M.J., and Obrosova I.G. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells. Free Radic Biol Med 40 (2006) 1454-1465
108. Nakamura S., Li H., Adijiang A., Pischetsrieder M., and Niwa T. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant 22 (2007) 2165-2174
109. Balakumar P., Arora M.K., and Singh M. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol Res (2009) 10.1016/j.phrs.2009.01.010
110. Pitrosch F., Herbrig K., Kinder B., Passauer J., Fisher S., and Gross P. Rosiglitazone improves glomerular hyperfilteration, renal endothelial dysfunction and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54 (2005) 2206-2211
111. Bonnet F., and Cooper M.E. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diab Metab 26 (2000) 254-264
112. Rosario R.F., and Sharma P. Lipids and diabetic nephropathy. Curr Diab Rep 6 (2006) 455-462
113. Park C.W., Zhang Y., Zhang X., Wu J., Chen L., Cha D.R., et al. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69 (2006) 1511-1517
114. Chen Y.J., and Quilley J. Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase expression and enhanced renal prostaglandin release. J Phamacol Exp Therap 324 (2008) 658-663
115. Calkin A.C., Giunti S., Dahm K.A.J., Allen T.J., Cooper M.E., and Thomas M.C. PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dil Trans 21 (2006) 2399-2405
116. Zhang H., Saha J., Byun J., Schin M.L., Lorenz M., and Kennedy R.T. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolic abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Ren Physiol 295 (2008) F1071-F1081
117. Okada T., Wada J., Hida K., Equchi J., Hashimoto I., Baba M., et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 55 (2006) 1666-1677
118. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Ren Physiol 292 (2007) F1141-F1150
119. Ko G.J., Kang Y.S., Han S.Y., Lee M.H., Sang H.K., and Han K.H. Pioglitazone attenuates diabetic nephropathy through an antiinflammatory mechanism in type 2 diabetic rats. Nephrol Dil Trans 23 (2008) 2750-2760
120. Matsui T., Yamagishi S., Ueda S., Nakamura K., Imaizumi T., Takeuchi M., et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advance glycation end-products (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 35 (2007) 482-489
121. Shibata T., Takeuchi S., Yokota S., Kakimoto K., Yonemori F., and Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in zucker diabetic rats. Br J Pharmacol 130 (2000) 495-504
122. Yokozawa T., Yamabe N., Cho E.J., Nakagawa T., and Oowada S. A study on the effects to diabetic nephropathy of Hachimi-jio-gan in rats. Nephron Exp Nephrol 97 (2004) e38-48
123. Anjaneyulu M., and Chopra K. Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 31 (2004) 244-248
124. Zhu H.W., Shi Z.F., and Chen Y.Y. Effect of extract of ginkgo bilboa leaf on early diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi 25 (2005) 889-891
125. Liu G., Guan G.J., Qi T.G., Fu Y.Q., Li X.G., Sun Y., et al. Protective effects of Salvia miltiorrhiza on rats with streptozotocin diabetes and its mechanism. Zhong Xi Yi Jie He Xue Bao 3 (2005) 459-462
126. Sharma S., Kulkarni S.K., and Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 33 (2006) 940-945
127. Zhang Y.W., Xie D., Chen Y.X., Zhang H.Y., and Xia Z.X. Protective effect of Gui Qi mixture on the progression of diabetic nephropathy in rats. Exp Clin Endocrinol Diabetes 114 (2006) 563-568
128. Sharma S., Anjaneyulu M., Kulkarni S.K., and Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 76 (2006) 69-75
129. Zhang Y.W., Xie D., Xia B., Zhen R.T., Liu I.M., and Cheng J.T. Suppression of transforming growth factor-beta1 gene expression by Danggui buxue tang, a traditional Chinese herbal preparation, in retarding the progress of renal damage in streptozotocin-induced diabetic rats. Horm Metab Res 38 (2006) 82-88
130. Kim C.S., Sohn E.J., Kim Y.S., Jung D.H., Jang D.S., Lee Y.M., et al. Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic goto-kakizaki rats. J Ethnopharmacol 111 (2007) 240-247
131. Al-Qattan K., Thomson M., and Ali M. Garlic (Allium sativum) and ginger (Zingiber officinale) attenuate structural nephropathy progression in streptozotocin-induced diabetic rats. Eur Soc Clin Nut Metabo 3 (2008) e62-71
132. Liu W., Tang F., Deng Y., Li X., Lan T., Zhang X., et al. Berberine reduces fibronectin and collagen accumulation in rat glomerular mesangial cells cultured under high glucose condition. Mol Cell Biochem 1 (2009) 10.1007/s11010-008-0024-y
133. Li X., Xiao Y., Gao H., Li B., Xu L., Cheng M., et al. Grape seed proanthocyanidins ameliorate diabetic nephropathy via modulation of levels of AGE, RAGE and CTGF. Nephron Exp Nephrol 111 (2009) e31-e41
134. Sato S., Kawamura H., Takemoto M., Maezawa Y., Fujimoto M., Shimoyama T., et al. Halofuginone prevents extracellular matrix deposition in diabetic nephropathy. Biochem Biophys Res Commun 379 (2009) 411-416
135. Ribaldo P.D., Souza D.S., Biswas S.K., Block K., Lopes de Faria J.M., and Lopes de Faria J.B. Green tea (Camellia sinensis) attenuates nephropathy by downregulating Nox4 NADPH oxidase in diabetic spontaneously hypertensive rats. J Nutr 139 (2009) 96-100